Emad Abro
YOU?
Author Swipe
View article: Reviewing the Eras: A Retrospective, Single-Centre Review of Peripheral Blood Stem Cell Mobilisation Following Bortezomib, Lenalidomide and Dexamethasone Induction in Comparison to Bortezomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Reviewing the Eras: A Retrospective, Single-Centre Review of Peripheral Blood Stem Cell Mobilisation Following Bortezomib, Lenalidomide and Dexamethasone Induction in Comparison to Bortezomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma Open
In Australia, a triplet induction regimen with bortezomib, lenalidomide and dexamethasone (VRd) for newly diagnosed transplant eligible multiple myeloma (ND-TE-MM) patients has been standard of care since 2020, replacing bortezomib, cyclop…
View article: Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC) Open
PURPOSE A prospective phase II study examined the safety and efficacy of venetoclax combined with low-dose cytarabine (LDAC) in AML at first measurable residual disease (MRD) or oligoblastic relapse. METHODS Patients with either MRD (≥1 lo…
View article: Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen
Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen Open
Introduction: There are a lack of randomized trials to guide therapy for relapsed AL amyloidosis with treatment regimens generally extrapolated from experience in multiple myeloma. Methods: We conducted a retrospective review of bortezomib…
View article: Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy
Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy Open
Background: Achievement of rapid and deep hematological responses is critical in the treatment of AL amyloidosis, particularly for those patients with advanced cardiac involvement. The timing and depth of FLC reduction that defines subopti…
View article: PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS
PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS Open
Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Light-chain (AL) amyloidosis arises from a plasma cell clone that overproduces immunoglobulin light chains. These light chains deposit within tissues and organs an…
View article: 2749 The spectrum of neuropathy in hereditary transthyretin amyloidosis (ATTRv) in Australia
2749 The spectrum of neuropathy in hereditary transthyretin amyloidosis (ATTRv) in Australia Open
Objectives Hereditary Transthyretin amyloidosis (ATTRv) is characterised by progressive sensorimotor and autonomic neuropathy, and cardiac failure. We aim to describe the spectrum of ATTRv neuropathy in Australia. Methods A retrospective a…
View article: Clinical impact of <i>NPM1</i>-mutant molecular persistence after chemotherapy for acute myeloid leukemia
Clinical impact of <i>NPM1</i>-mutant molecular persistence after chemotherapy for acute myeloid leukemia Open
Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persisten…
View article: LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma Open
Blockade of the PD-1 axis has modest efficacy in diffuse large B-cell lymphoma (DLBCL), but data regarding LAG3 are sparse. The impact of LAG3 digital gene expression was tested in 309 patients with DLBCL treated with standard chemoimmunot…
View article: Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance Open
Key Points Practices in early-stage FL are variable and include radiation alone, systemic therapy, CMT, or observation. Each practice resulted in similar excellent outcomes; randomized trials are required to determine the optimal treatment.
View article: ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN PATIENTS WITH DLBCL TREATED WITH R‐CHOP
ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN PATIENTS WITH DLBCL TREATED WITH R‐CHOP Open
Introduction: Immune checkpoint therapy has revolutionised the treatment of metastatic solid tumours. LAG3 is an immune checkpoint that is highly expressed on a variety of immune cells including a sub-population of ‘exhausted’ T cells. We …